The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation

RATIONALE: Brolucizumab is a novel anti-vascular endothelial growth factor agent with clinical trials demonstrating excellent efficacy for neovascular age-related macular degeneration (AMD) in both visual and anatomic outcomes. However, there is concern of intraocular inflammation (IOI), and we prop...

Descripción completa

Detalles Bibliográficos
Autores principales: Shigemoto, Yumi, Sakurada, Yoichi, Fukuda, Yoshiko, Matsubara, Mio, Parikh, Ravi, Kashiwagi, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542137/
https://www.ncbi.nlm.nih.gov/pubmed/34678906
http://dx.doi.org/10.1097/MD.0000000000027580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542137/
https://www.ncbi.nlm.nih.gov/pubmed/34678906
http://dx.doi.org/10.1097/MD.0000000000027580

Ejemplares similares